Microfluidics Patents

Microfluidics patents cover lab-on-chip integrated fluidic circuit fabrication innovations; droplet microfluidics generation and emulsion PCR innovations; single-cell sequencing and barcoded bead innovations; and organ-on-chip microphysiological system innovations — with IP held by genomics companies, diagnostics firms, and academic spin-outs: MAJOR MICROFLUIDICS PATENT HOLDERS: ILLUMINA: 2,000+; specific lab-on-chip innovations (specific specific SBS sequencing-by-synthesis flow cell: specific specific PDMS glass flow cell 100-600 μm channel from specific specific nanowell patterning 1 μm pitch 300-nm wells from specific specific 20 billion clusters/flow cell NovaSeq X from specific specific cluster generation: specific specific bridge amplification isothermal from specific specific exclusion amplification ExAmp from specific specific 300 bp paired-end 2×150 PE300 from specific specific reversible terminator: specific specific 3'-OH blocked fluoro-dNTP from specific specific SBS cycle: specific specific incorporate image strip wash from specific specific base-calling CNNs GPU 30 min NovaSeq X); 10X GENOMICS: 500+; specific single-cell innovations (specific specific Chromium droplet: specific specific GEM gel bead in emulsion from specific specific 1 nL droplet co-encapsulation from specific specific barcoded bead 3M barcode library from specific specific 10,000 cells per run from specific specific scRNA-seq: specific specific 10x v3 chemistry from specific specific poly-A capture UMI from specific specific 10,000 genes per cell from specific specific ATAC-seq chromatin accessibility from specific specific spatial transcriptomics: specific specific Visium 10 μm spot 55 μm pitch from specific specific in situ RNA capture from specific specific 6.5 mm × 6.5 mm FOV); STANDARD BIOTOOLS / FLUIDIGM: 1,000+; specific IFC innovations (specific specific integrated fluidic circuit IFC: specific specific PDMS multilayer soft lithography from specific specific 96×96 matrix 9,216 individual reactions from specific specific push-up valve PDMS membrane from specific specific pneumatic 15 psi actuation from specific specific BioMark RT-PCR 100× miniaturized); BIO-RAD: 500+; EMULATE: 200+.

PDMS soft lithography microchannel fabrication and valve innovations; droplet microfluidics generation and surfactant stabilization innovations; and digital PCR dPCR partitioning and absolute quantification innovations represent core microfluidics patent domains: PDMS SOFT LITHOGRAPHY PATENTS: WHITESIDES/HARVARD; STANFORD; CALTECH; MIT; FLUIDIGM: specific fabrication innovations (specific specific PDMS microfluidics: specific specific Sylgard 184 10:1 base:curing 65°C 1h from specific specific SU-8 master 50-200 μm tall from specific specific oxygen plasma bond glass/PDMS 5 min from specific specific channel: specific specific 10-500 μm width 5-100 μm height from specific specific 0.5-20 μL/min flow rate from specific specific Re 0.01-10 laminar from specific specific multilayer: specific specific alignment layer 2 ±5 μm from specific specific push-up valve: specific specific deflection 50 μm at 15 psi from specific specific Quake valve: specific specific normally-closed push-down from specific specific 0.5 nL dead volume from specific specific peristaltic pump: specific specific 3-valve sequential actuation from specific specific 5-100 nL/stroke from specific specific thermoplastic: specific specific COC COP PMMA hot emboss 150°C 5 min from specific specific injection mold 30 s cycle from specific specific production vs. PDMS 100× lower cost from specific specific nanofabrication: specific specific SiO₂ etch KOH 54.7° <111> 1 μm/min from specific specific DUV 248 nm 0.5 μm feature from specific specific PIE plasma ALD oxide); DROPLET MICROFLUIDICS PATENTS: RAINDANCE; BIO-RAD; ENCAPSULATION SYSTEMS; GNUBIO; 10X: specific droplet innovations (specific specific droplet generation: specific specific T-junction cross-junction from specific specific 10-100 pL to 10 nL volume from specific specific oil phase: specific specific HFE-7500 FC-40 from specific specific Pico-Surf 2% w/v surfactant from specific specific monodispersity CV <2% from specific specific generation rate: specific specific 1,000-10,000 droplets/sec from specific specific 10⁸ per hour from specific specific emulsion PCR ePCR: specific specific 1 template per droplet from specific specific 2×10⁷/μL amplicons vs. 10^9/mL from specific specific 30 cycles 1 min/cycle thermocycle chip from specific specific FACS droplet sort: specific specific 1 kHz fluorescence gate from specific specific SAW acoustic sort 30 kHz 100 nL/event from specific specific picoinject: specific specific electroporation addition 10-100 fL to droplet from specific specific pL library addition); DIGITAL PCR PATENTS: BIO-RAD; RAINTREE; LIFE TECHNOLOGIES; QUANTALIFE: specific dPCR innovations (specific specific droplet digital PCR ddPCR: specific specific 20,000 water-in-oil 20 nL partitions from specific specific Poisson distribution: specific specific λ = -ln(1-p) copies/partition from specific specific absolute quantification no calibration from specific specific LOD 1-5 copies/mL from specific specific 6 orders dynamic range from specific specific chip dPCR: specific specific 20,000 nanoliter chambers from specific specific thermal PCR 55-95°C chip heater from specific specific quantitative sensitivity 0.001% allele fraction from specific specific RainDrop Plus 10M partitions 5 μL 1 nL).

Organ-on-chip microphysiological system MPS and barrier function innovations; microfluidic electrochemical biosensor and lateral flow assay innovations; and point-of-care nucleic acid amplification and sample-to-answer chip innovations represent additional microfluidics patent domains: ORGAN-ON-CHIP PATENTS: EMULATE; WYSS INSTITUTE; VANDERBILT; CN BIO; MIMETAS: specific OoC innovations (specific specific lung-on-chip: specific specific PDMS dual-channel from specific specific alveolar epithelial ATII cells from specific specific vascular HUVEC from specific specific 10-20 μm membrane 0.4 μm pore from specific specific cyclic stretch 10% strain 0.2 Hz from specific specific TEER transepithelial electrical resistance 500-2,000 Ω·cm² from specific specific barrier permeability P_app 10⁻⁶ cm/s paracellular from specific specific gut-on-chip: specific specific villous fold peristalsis 0.01-0.1 Hz from specific specific Caco-2 HCT-116 Lgr5+ organoid from specific specific mucus layer 10-100 μm from specific specific microbiome co-culture anaerobic from specific specific liver-on-chip: specific specific hepatocyte oxygen gradient 0-160 μM from specific specific CYP450 3A4 induction 5× rifampin from specific specific albumin 1 μg/mL/day from specific specific kidney-on-chip: specific specific PTEC proximal tubule from specific specific OAT1 transporter cisplatin nephrotoxicity); BIOSENSOR PATENTS: I-STAT/ABBOTT; IDEX BIORESEARCH; EPOCAL; CALIPER LIFE SCIENCES: specific biosensor innovations (specific specific microfluidic electrochemical: specific specific ISE ion selective electrode from specific specific amperometric glucose GOx Pt +0.7 V from specific specific CV cyclic voltammetry from specific specific EIS electrochemical impedance spectroscopy from specific specific EC-SOC electrowetting from specific specific integrated microfluidic: specific specific microvalve pump on-chip from specific specific LAMP isothermal amplification 65°C 30 min from specific specific Cas12 CRISPR detection from specific specific LFiA lateral flow immuno chromatography from specific specific nitrocellulose 25 μm pore from specific specific conjugate AuNP 40 nm detection); POINT-OF-CARE PATENTS: CEPHEID; BIOFIRE; BIOMÉRIEUX; BOSCH; ABAXIS: specific POC innovations (specific specific integrated sample-to-answer: specific specific Cepheid GeneXpert: specific specific lysis bead-beating from specific specific extraction silica membrane from specific specific qPCR 45 cycles 45 min from specific specific MRSA SA SARS-CoV-2 multiplex from specific specific BioFire FilmArray: specific specific multiplex PCR 22 targets from specific specific GI respiratory panel from specific specific BioFire BCID 43 targets from specific specific chip: specific specific Abbott ID NOW LAMP 13 min from specific specific Roche Cobas Liat PCR 20 min from specific specific on-chip centrifugal: specific specific Lab-on-disc CD-format centrifuge 500-2,000 rpm from specific specific blood plasma separation 1,000g).

Microfluidics startup IP strategy must navigate Illumina (2,000+) and Standard BioTools (1,000+) broad lab-on-chip and IFC IP; understand that Harvard Whitesides group holds foundational PDMS soft lithography IP (largely expired or licensed) and Caltech holds Quake valve IP; identify whitespace in novel organ-on-chip applications, microfluidic biosensors for specific analytes, novel droplet operations, and thermoplastic mass-production fabrication replacing PDMS — while understanding that point-of-care diagnostics represents a $25B market with significant unmet need: MICROFLUIDICS STARTUP IP STRATEGY: UNDERSTAND THE MICROFLUIDICS PATENT LANDSCAPE — FOUNDATIONAL PDMS SOFT LITHOGRAPHY IS EXPIRED; COMMERCIAL APPLICATIONS ARE ACTIVE: Harvard Whitesides PDMS soft lithography foundational patents expired 2015-2020 — fabrication processes are largely open; Fluidigm (now Standard BioTools) Quake valve pneumatic IFC IP is active; commercial application-specific IP (Illumina flow cell sequencing, 10x Genomics barcoded droplet, Bio-Rad ddPCR) is active and covers specific products; ORGAN-ON-CHIP AND MICROPHYSIOLOGICAL SYSTEMS ARE THE HIGHEST-GROWTH LEAST-CONSOLIDATED IP DOMAIN: Emulate and Wyss hold core lung-on-chip and gut-on-chip IP, but organ-specific applications (pancreas, brain, tumor) and multi-organ systems remain less encumbered; the FDA&apos;s 2022 FDA Modernization Act 2.0 (reduces animal testing requirements, recognizes microphysiological systems) creates a regulatory moat for validated OoC-based drug testing platforms; WHEN TO PATENT IN MICROFLUIDICS: NOVEL CHIP WITH MEASURED BIOLOGICAL ASSAY PERFORMANCE: specific novel microfluidic device (specific specific chip geometry + specific specific fabrication material/method + specific specific assay/operation) with specific measured performance (specific specific analyte detection LOD fM/pM/nM or cells/mL + specific specific assay time minutes at specific specific sample volume μL + specific specific sensitivity/specificity % at specific specific clinical matrix + specific specific throughput reactions/chip or cells/run + specific specific TEER Ω·cm² or P_app cm/s for OoC barrier function) vs. specific specific bench reference (specific specific Cepheid GeneXpert 45 min MRSA or specific specific Bio-Rad ddPCR LOD 1-5 copies/mL or specific specific Illumina NovaSeq 20B clusters/flow cell) — measured assay performance vs. commercial instrument benchmark is the critical microfluidics IP metric; KEY FTO CHECKLIST: Illumina SBS nanowell 1 μm 20B clusters 300 bp PE300 bridge ExAmp reversible terminator CNN; 10x GEM 1 nL droplet 3M barcode 10K cells scRNA-seq Visium 10 μm; Fluidigm IFC 96×96 9,216 push-up valve 15 psi pneumatic; Bio-Rad ddPCR 20,000 20 nL Poisson LOD 1-5 copies/mL 6-order; PDMS SU-8 master O₂ plasma bond multilayer Quake valve 0.5 nL; droplet T-junction HFE-7500 Pico-Surf CV<2% 10⁸/hr SAW sort Cas12 LAMP; organ-on-chip lung TEER 2,000 Ω stretch 10% 0.2 Hz gut Lgr5+ mucus liver CYP3A4 kidney OAT1; GeneXpert lysis qPCR 45 min BioFire multiplex 22-43 targets LAMP Abbott 13 min centrifugal CD-format.